These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
383 related articles for article (PubMed ID: 38443448)
21. A costimulatory chimeric antigen receptor targeting TROP2 enhances the cytotoxicity of NK cells expressing a T cell receptor reactive to human papillomavirus type 16 E7. Poorebrahim M; Quiros-Fernandez I; Marmé F; Burdach SE; Cid-Arregui A Cancer Lett; 2023 Jul; 566():216242. PubMed ID: 37217069 [TBL] [Abstract][Full Text] [Related]
22. Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges. Kong JC; Sa'ad MA; Vijayan HM; Ravichandran M; Balakrishnan V; Tham SK; Tye GJ Front Immunol; 2024; 15():1384039. PubMed ID: 38726000 [TBL] [Abstract][Full Text] [Related]
23. NK Cells Equipped With a Chimeric Antigen Receptor That Overcomes Inhibition by HLA Class I for Adoptive Transfer of CAR-NK Cells. Zhuang X; Long EO Front Immunol; 2022; 13():840844. PubMed ID: 35585985 [TBL] [Abstract][Full Text] [Related]
25. Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy. Zhang C; Hu Y; Xiao W; Tian Z Cell Mol Immunol; 2021 Sep; 18(9):2083-2100. PubMed ID: 34267335 [TBL] [Abstract][Full Text] [Related]
26. Potential of chimeric antigen receptor (CAR)-redirected immune cells in breast cancer therapies: Recent advances. Nikoo M; Rudiansyah M; Bokov DO; Jainakbaev NT; Suksatan W; Ansari MJ; Thangavelu L; Chupradit S; Zamani A; Adili A; Shomali N; Akbari M J Cell Mol Med; 2022 Aug; 26(15):4137-4156. PubMed ID: 35762299 [TBL] [Abstract][Full Text] [Related]
27. Reprogramming natural killer cells for cancer therapy. Wang K; Wang L; Wang Y; Xiao L; Wei J; Hu Y; Wang D; Huang H Mol Ther; 2024 Sep; 32(9):2835-2855. PubMed ID: 38273655 [TBL] [Abstract][Full Text] [Related]
28. CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies. Marofi F; Saleh MM; Rahman HS; Suksatan W; Al-Gazally ME; Abdelbasset WK; Thangavelu L; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Pathak Y; Naimi A; Baradaran B; Nikoo M; Khiavi FM Stem Cell Res Ther; 2021 Jul; 12(1):374. PubMed ID: 34215336 [TBL] [Abstract][Full Text] [Related]
29. Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma. Yu M; Luo H; Fan M; Wu X; Shi B; Di S; Liu Y; Pan Z; Jiang H; Li Z Mol Ther; 2018 Feb; 26(2):366-378. PubMed ID: 29339014 [TBL] [Abstract][Full Text] [Related]
30. Charting a killer course to the solid tumor: strategies to recruit and activate NK cells in the tumor microenvironment. Portillo AL; Monteiro JK; Rojas EA; Ritchie TM; Gillgrass A; Ashkar AA Front Immunol; 2023; 14():1286750. PubMed ID: 38022679 [TBL] [Abstract][Full Text] [Related]
31. Next-generation chimeric antigen receptors for T- and natural killer-cell therapies against cancer. Li Y; Rezvani K; Rafei H Immunol Rev; 2023 Nov; 320(1):217-235. PubMed ID: 37548050 [TBL] [Abstract][Full Text] [Related]
32. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities. Hu W; Wang G; Huang D; Sui M; Xu Y Front Immunol; 2019; 10():1205. PubMed ID: 31214177 [TBL] [Abstract][Full Text] [Related]
33. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies. Matosevic S J Immunol Res; 2018; 2018():4054815. PubMed ID: 30306093 [TBL] [Abstract][Full Text] [Related]
34. Natural killer cell-based strategies for immunotherapy of cancer. Vaněk O; Kalousková B; Abreu C; Nejadebrahim S; Skořepa O Adv Protein Chem Struct Biol; 2022; 129():91-133. PubMed ID: 35305726 [TBL] [Abstract][Full Text] [Related]
35. Building a Better Defense: Expanding and Improving Natural Killer Cells for Adoptive Cell Therapy. Maia A; Tarannum M; Lérias JR; Piccinelli S; Borrego LM; Maeurer M; Romee R; Castillo-Martin M Cells; 2024 Mar; 13(5):. PubMed ID: 38474415 [TBL] [Abstract][Full Text] [Related]
36. Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors. Jan CI; Huang SW; Canoll P; Bruce JN; Lin YC; Pan CM; Lu HM; Chiu SC; Cho DY J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663641 [TBL] [Abstract][Full Text] [Related]